Lilly’s Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast…
Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial. Treatment with two years of Verzenio plus endocrine therapy (ET) demonstrated a…
Read More...
Read More...